Sartorius Stedim Biotech S.A.

BATS-CHIXE:DIMP Stock Report

Market Cap: €16.3b

Sartorius Stedim Biotech Valuation

Is DIMP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DIMP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DIMP (€168.38) is trading above our estimate of fair value (€117.14)

Significantly Below Fair Value: DIMP is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DIMP?

Key metric: As DIMP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DIMP. This is calculated by dividing DIMP's market cap by their current earnings.
What is DIMP's PE Ratio?
PE Ratio101.4x
Earnings€160.60m
Market Cap€16.28b

Price to Earnings Ratio vs Peers

How does DIMP's PE Ratio compare to its peers?

The above table shows the PE ratio for DIMP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.9x
ERGO Ergomed
46.7x14.2%UK£701.1m
HVO hVIVO
9.9x-15.2%UK£172.8m
HIK Hikma Pharmaceuticals
17.8x11.2%UK£4.0b
GSK GSK
21.3x22.4%UK£53.5b
DIMP Sartorius Stedim Biotech
101.4x31.9%€16.3b

Price-To-Earnings vs Peers: DIMP is expensive based on its Price-To-Earnings Ratio (101.4x) compared to the peer average (16.3x).

Price to Earnings Ratio vs Industry

How does DIMP's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
No. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: DIMP is expensive based on its Price-To-Earnings Ratio (101.4x) compared to the European Life Sciences industry average (37.1x).

Price to Earnings Ratio vs Fair Ratio

What is DIMP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DIMP PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio101.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate DIMP's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DIMP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€168.38
€220.67
+31.1%
18.2%€310.00€134.00n/a15
Nov ’25€187.98
€220.67
+17.4%
18.2%€310.00€134.00n/a15
Oct ’25€189.25
€213.93
+13.0%
20.5%€310.00€134.00n/a14
Sep ’25€184.00
€207.31
+12.7%
20.8%€310.00€134.00n/a13
Aug ’25€165.25
€207.31
+25.5%
20.8%€310.00€134.00n/a13
Jul ’25n/a
€247.17
0%
17.8%€360.00€180.00n/a12
Jun ’25€184.65
€248.83
+34.8%
16.8%€360.00€200.00n/a12
May ’25n/a
€251.33
0%
16.9%€360.00€200.00n/a12
Apr ’25€267.15
€261.23
-2.2%
15.8%€360.00€205.00n/a12
Mar ’25€250.05
€254.69
+1.9%
17.1%€360.00€190.00n/a14
Feb ’25n/a
€253.12
0%
18.3%€360.00€190.00n/a14
Jan ’25n/a
€230.56
0%
14.8%€310.00€175.00n/a12
Dec ’24n/a
€224.31
0%
14.5%€310.00€175.00n/a12
Nov ’24€172.78
€252.42
+46.1%
22.5%€390.00€175.00€187.9812
Oct ’24€222.80
€308.73
+38.6%
12.3%€390.00€265.00€189.2511
Sep ’24n/a
€306.45
0%
12.5%€390.00€270.00€184.0011
Aug ’24€269.80
€303.73
+12.6%
13.5%€390.00€250.00€165.2511
Jul ’24€212.60
€334.18
+57.2%
22.7%€530.00€250.00n/a11
Jun ’24n/a
€363.82
0%
18.5%€530.00€285.00€184.6511
May ’24€237.50
€376.70
+58.6%
17.6%€530.00€300.00n/a10
Apr ’24€275.70
€395.27
+43.4%
10.5%€455.00€306.00€267.1511
Mar ’24€330.60
€395.91
+19.8%
10.7%€455.00€306.00€250.0511
Feb ’24€323.45
€394.73
+22.0%
10.3%€455.00€306.00n/a11
Jan ’24n/a
€411.20
0%
12.3%€470.00€290.00n/a10
Dec ’23€336.40
€411.20
+22.2%
12.3%€470.00€290.00n/a10
Nov ’23€314.30
€418.45
+33.1%
13.0%€497.00€290.00€172.7811

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€820.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€46.50

7D

-3.8%

1Y

-26.2%

hVIVO

UK£172.8m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.25

7D

-10.9%

1Y

39.6%

Dermapharm Holding

€1.9b

Manufactures and sells off-patent branded pharmaceutical products in Germany.

0A5J

€34.35

7D

7.7%

1Y

-14.5%